This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings
by Ekta Bagri
Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.
Here's Why You Should Invest in Intuitive Surgical Right Now
by Zacks Equity Research
Intuitive Surgical (ISRG) gains on solid Q1 results and strength in da Vinci platform.
5 Winning Stocks With Superb Efficiency Level
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reports wider-than-expected Q1 loss. Its three key pipeline candidates - ralinepag, etrasimod and Olorinab/APD371 - remain in focus.
Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag
by Zacks Equity Research
Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.
Exelixis (EXEL) Q1 Earnings & Sales Top on Cabometyx Strength
by Zacks Equity Research
Exelixis (EXEL) posted a strong performance in the first-quarter as lead drug Cabometyx made further inroads in the RCC market.
Is a Beat in the Cards for Exelixis (EXEL) in Q1 Earnings?
by Zacks Equity Research
Exelixis is likely to beat on earnings when it reports first-quarter results (May 2) driven by strong growth of Cabometyx sales.
Calithera's Kidney Cancer Candidate Gets Fast Track Status
by Zacks Equity Research
Calithera Biosciences' (CALA) lead pipeline candidate, CB-839, gets fast track status in the United States for the treatment of kidney cancer.
Exelixis (EXEL) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
Moving Average Crossover Alert: Exelixis, Inc. (EXEL)
by Zacks Equity Research
Moving Average Crossover Alert: Exelixis, Inc. (EXEL)
Weakness Seen in Exelixis (EXEL) Estimates: Should You Stay Away?
by Zacks Equity Research
Exelixis (EXEL) has witnessed a significant price decline in the past four weeks, and has seen negative earnings estimate revisions for the current quarter and year.
Why Is Exelixis (EXEL) Down 17.2% Since Its Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis Cabometyx Gets Positive CHMP Opinion in Europe
by Zacks Equity Research
Exelixis' European partner, Ipsen, obtains positive opinion from the CHMP for the use of Cabometyx in the first-line treatment of advanced renal cell carcinoma.
Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat (revised)
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.
Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down
by Zacks Equity Research
Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.
Exelixis (EXEL) Q4 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.
Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4
by Zacks Equity Research
Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.
Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.
Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
Corcept's (CORT) Earnings and Sales Meet Estimates in Q4
by Zacks Equity Research
Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y
by Zacks Equity Research
Medicines Company (MDCO) incurs wider-than-expected loss in the fourth quarter of 2017. Moreover, the top line declines year over year on low Angiomax sales.
Will Mylan (MYL) Disappoint Investors This Earnings Season?
by Zacks Equity Research
During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.
Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?
by Zacks Equity Research
Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.
What's in Store for Agenus (AGEN) This Earnings Season?
by Zacks Equity Research
Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.